IACM-Bulletin of 26 August 2013 | UFCM

August 27, 2013 – 09:24

Source IACM Here
• United States: Illinois is the twentieth state to legalize the medical use of cannabis
• Science / Man: A study on the long term indicates that cannabis extract does not affect cognition
• Briefly
• A look at the past

United States: Illinois is the twentieth state to legalize the medical use of cannabis

On 1 August, the Illinois Governor Pat Quinn signed into law that authorizes the medical use of cannabis in this state. After California, it is the most populous state to allow such use. "Over the years, the veterans and the brave patients who fight against terrible diseases have touched me, " said the Governor. "It is absolutely necessary to relieve. "The law, which takes effect January 1, allows patients whose diagnosis is part of a list of 35 diseases such as cancer, Parkinson's disease or multiple sclerosis to use cannabis when he is prescribed by a doctor of that State.
This program, that those in favor of the medical use of cannabis recognized as the strictest in the country, says there must be a written certification from a physician, a patient card recorded with a photo ID and a electronic verification system. Nineteen other states and the District of Columbia have laws regarding the medical use of cannabis. The Illinois law states that patients can get every two weeks to 2, 5 ounces (about 70 grams). Cannabis must be grown and distributed in Illinois.
Reuters August 1, 2013

Science / Man: A study on the long term indicates that cannabis extract does not affect cognition

The company GW Pharmaceuticals announced in a press release that the cannabis extract Sativex has no negative effect on cognitive performance. This statement results from a placebo-controlled study of 12 months, which included 121 patients with spasticity due to multiple sclerosis. The statement said that "this study confirms the safety and efficacy of Sativex in the long term. "
The study was requested by the regulatory authority of the United Kingdom as part of the process of post-approval. Its primary objective is to evaluate the side effects of Sativex on cognitive function and mood. It was noted in both groups, the placebo group and the group that was administered Sativex, a slight improvement in cognitive function from beginning to end of the study. Similarly, the change of mood in both groups over the twelve months of the study, proved identical.
Press release by GW Pharmaceuticals of August 5. 2013

In short

Uruguay: President to defend the United Nations plan to legalize cannabis spokesman Uruguayan President Jose Mujica said that it intends, in September, before the General Assembly of the United Nations, present an innovative plan for authorization of cannabis. The Chamber of Deputies voted on July 31 the creation of a government entity to control the cultivation and sale of cannabis. The sale of cannabis and the ability to make a crop for recreational use in clubs are also considered. The measure will be introduced in the Senate later this year. Associated Press August 2, 2013
United States: The sale of medicinal cannabis began in Washington DC District of Columbia made the first legal sale of medicinal cannabis for at least 75 years. A 51 year old man bought a little less than an ounce of marijuana, July 29, at the Capital City Care clinic. The center offers three different varieties, prices vary between 380 and 440 dollars an ounce (about 28 grams). UPI of 30 July 2013
Science / Man: THC concentrations of endocannabinoids influence the administration of a dose of 20 mg of oral THC in 30 healthy volunteers induced higher concentrations of endocannabinoids anandamide, 2-AG, palmitoyl ethanolamide, and oleoylethanolamide, 2 or 3 hours after administration, compared with the placebo group. The authors concluded that "exogenous cannabinoids may lead to changes in the endocannabinoid system, which can be detected in plasma. "Institute of Clinical Pharmacology, Goethe-University, Frankfurt am Main, Germany. Walter C, et al. J Clin Psychopharmacol. July 29, 2013. [In press]
Australia cannabinoid content of cannabis The mean levels of cannabinoids measured on 206 samples of cannabis seized by police are 14.9% for THC, 0.14% for the CBD, 1.9% for CBG (cannabigerol) and traces of other cannabinoids. National Drug and Alcohol Research Centre, University of New South Wales, Sydney, Australia. Swift W, et al. PLoS One2013, 8 (7): e70052.
Science / Animal: THC and CBD reduce rates of pro-inflammatory interleukin 17 transmitters In the animal model studies, THC and CBD (cannabidiol), depending on the dose used, suppressed the production and secretion cytokine interleukin 17 (IL-17). This pro-inflammatory substance increases in the case of inflammatory diseases such as multiple sclerosis. Treatment with CBD has also led to an increased level of cytokine IL-10 anti-inflammatory. Sackler Faculty of Medicine, Tel Aviv University, Israel. Kozela E, et al. J Neuroimmune Pharmacol. July 28, 2013 [in press]
Science / Animal: The THCA reduces nausea in the animal model The THCA (THC acid), a non-psychoactive precursor of THC cannabis plant, the heat turns into THC, reduced nausea rats and mice. This effect was sent by the CB1 receptor. The authors concluded that "THCA could be more potent than THC treatment of nausea and vomiting alternative." Department of Psychology, University of Guelph, Canada. Rock E, et al. Br J Pharmacol. July 25, 2013. [In press]
Science / Animal: A local application of THC reduces inflammation that causes allergy Local application of THC reduces inflammation of allergic dermatitis in mice independently of cannabinoid receptors by reducing pro-inflammatory mediators from cells skin. The authors wrote that these results have "significant implications for the development of future strategies involving cannabinoids in the treatment of inflammatory skin diseases. "Laboratory of Experimental Dermatology, Department of Dermatology and Allergy, University of Bonn, Germany. Gaffal E, et al. Allergy. July 29, 2013. [In press]
Science / Animal: The COX-2 inhibitors reduce anxiety by increasing the concentration of endocannabinoid Increased cannabinoid signal was induced by inhibition of the enzyme cyclooxygenase-2 (COX-2) and reduced the anxiety in mice. The authors concluded that increased levels of endocannabinoids present a varied therapeutic potential and is a viable approach. "Vanderbilt Institute of Chemical Biology, Vanderbilt University School of Medicine, Nashville, USA. Hermanson DJ, et al. Nat Neurosci. August 4, 2013. [In press]
Science / Man: If schizophrenia, cannabis use improves emotional memory A study of 28 patients with schizophrenia, half consumed cannabis and the other not, and 21 healthy subjects showed that emotional memory and functional in the region of the prefrontal lobe was preserved in the group of consumers. Centre de recherche Fernand-Seguin, Montreal, Canada. Bourque J, et al. Psychiatry Res. 2c July 2013. [In press]
Science / Animal: The THCV and CBDV reduce nausea in animal models of nausea, cannabidivarine natural cannabinoids (CBDV) and tetrahydrocannabivarin (THCV) suppressed behavior considered nausea in animals. The authors concluded "that these components may have therapeutic potential for reducing nausea. "Department of Psychology and Neuroscience Graduate Program, University of Guelph, Canada. Rock EM, et al. Br J Pharmacol. July 31, 2013. [In press]
Science / Animal: The CBDV has an anti-epileptic potential in three models of epilepsy (mouse), the natural cannabinoid cannabidivarin (CBDV) reduced seizures. The cannabinoid-1 receptor forwarded this. The authors wrote that "these results show the need for future clinical development CBDV for the treatment of epilepsy. "Reading School of Pharmacy, University of Reading, UK. Hill TD, et al. Br J Pharmacol. July 31, 2013. [In press]

Source: www.ufcmed.org

Стоматология ЮАО

Related posts:

  1. Animal Control Ocala Florida
  2. Animal Control Chicago Illinois
  3. Animal Control Joliet Illinois
  4. Animal Control of Indiana